Capital World Investors Fate Therapeutics Inc Transaction History

Capital World Investors

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$9.86 - $23.83 $26 Million - $62.9 Million	-2,639,795 Reduced 32.07%	5,591,517 $56.4 Million
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $20,787 - $35,627	-988 Reduced 0.01%	8,231,312 $184 Million
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $65.3 Million - $156 Million	3,672,627 Added 80.55%	8,232,300 $204 Million
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $38.6 Million - $78.4 Million	1,300,640 Added 39.91%	4,559,673 $177 Million
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $156 Million - $210 Million	3,259,033 New	3,259,033 $191 Million

177

113M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $126M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

Stay updated on Capital World Investors with notifications on news.